Cargando…

Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data

BACKGROUND: The recommendation for postoperative chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is based on prospective randomized trials. However, patients included in clinical trials do not often reflect the overall patient population treated in clinical practice. MATERIALS AND METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chikhladze, Sophia, Lederer, Ann-Kathrin, Kousoulas, Lampros, Reinmuth, Marilena, Sick, Olivia, Fichtner-Feigl, Stefan, Wittel, Uwe A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842534/ https://www.ncbi.nlm.nih.gov/pubmed/31706323 http://dx.doi.org/10.1186/s12957-019-1732-3

Ejemplares similares

Curative-intent pancreas resection for pancreatic metastases: surgical and oncological results
por: Chikhladze, Sophia, et al.
Publicado: (2020)

The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma
por: Ruess, Dietrich A., et al.
Publicado: (2015)

Clinical characteristics and outcome of patients with acute mesenteric ischemia: a retrospective cohort analysis
por: Martini, Verena, et al.
Publicado: (2022)

Hemoadsorption in a Case of Severe Septic Shock and Necrotizing Fasciitis Caused by Nontraumatic Renal Rupture due to Pyelonephritis with Obstructive Uropathy
por: Kousoulas, Lampros, et al.
Publicado: (2018)

Surgical pancreatic biopsies for cases with locally advanced pancreatic cancer with inconclusive histology after interventional biopsy
por: Klösges, Laura, et al.
Publicado: (2023)

Immune changes induced by periampullary adenocarcinoma are reversed after tumor resection and modulate the postoperative survival
por: Landerer, Anna, et al.
Publicado: (2023)

Bio‐absorbable sealants for reinforcing the pancreatic stump after distal pancreatectomy are critical
por: Kühlbrey, Christian M., et al.
Publicado: (2019)

Postoperative changes of the microbiome: are surgical complications related to the gut flora? A systematic review
por: Lederer, Ann-Kathrin, et al.
Publicado: (2017)

Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma
por: Rittmann, Marie-Claire, et al.
Publicado: (2021)

The impact of immunosuppression on postoperative graft function after graft-unrelated surgery: a retrospective controlled cohort study
por: Lederer, Ann-Kathrin, et al.
Publicado: (2019)

Clinical Characteristics and Outcomes of Surgical Patients with Intensive Care Unit Lengths of Stay of 90 Days and Greater
por: Martini, Verena, et al.
Publicado: (2017)

Severe hyperlactatemia in unselected surgical patients: retrospective analysis of prognostic outcome factors
por: Spiegelberg, Julia, et al.
Publicado: (2022)

Perioperative risk of pancreatic head resection—nomogram-based prediction of severe postoperative complications as a decisional aid for clinical practice
por: Hipp, J., et al.
Publicado: (2022)

Ogilvie’s syndrome—is there a cutoff diameter to proceed with upfront surgery?
por: Joechle, Katharina, et al.
Publicado: (2022)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
por: Li, Bo, et al.
Publicado: (2021)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
por: Braun, Lukas M., et al.
Publicado: (2020)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
por: Biagi, James J., et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Retrospective analyses of trends in pancreatic surgery: indications, operative techniques, and postoperative outcome of 1,120 pancreatic resections
por: Wittel, Uwe A, et al.
Publicado: (2015)

Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures
por: Braun, Lukas M., et al.
Publicado: (2020)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

Management and outcomes of intraductal papillary mucinous neoplasms
por: Hipp, J., et al.
Publicado: (2019)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer
por: Plundrich, Dorothea, et al.
Publicado: (2022)

Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma
por: Klett, Hagen, et al.
Publicado: (2018)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
por: Tang, Hui, et al.
Publicado: (2022)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_55hkni7hhrq7dav23mgbsj7n6p